## **Core Concept**
Alirocumab and Evolocumab are examples of drugs used in the management of hyperlipidemia. They belong to a class of medications known as PCSK9 inhibitors. PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is an enzyme that plays a critical role in the regulation of cholesterol levels by influencing the number of low-density lipoprotein receptors (LDLR) on the surface of liver cells.

## **Why the Correct Answer is Right**
Alirocumab and Evolocumab are PCSK9 inhibitors that work by binding to the PCSK9 protein, preventing it from interacting with and degrading LDL receptors on hepatocytes. This action increases the number of LDL receptors available on the liver cell surface, enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream. By reducing LDL-C levels, these drugs are used to lower the risk of cardiovascular events in patients with high cholesterol.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because Alirocumab and Evolocumab do not belong to this category; the correct category for them is PCSK9 inhibitors.
- **Option B:** This option might refer to another class of lipid-lowering drugs, but it is not accurate for Alirocumab and Evolocumab.
- **Option C:** While some drugs may work through similar pathways or have similar effects on lipid profiles, Alirocumab and Evolocumab are specifically PCSK9 inhibitors, not belonging to other categories like fibrates or bile acid sequestrants.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that PCSK9 inhibitors like Alirocumab and Evolocumab are often used in patients who require additional lowering of LDL-C beyond what can be achieved with statins alone or who cannot tolerate statins. These drugs have been shown to significantly reduce major adverse cardiovascular events.

## **Correct Answer:** . PCSK9 inhibitors